Andrew Gordon Patient

Andrew was diagnosed with Multiple Myeloma over six years ago. Andrew went through five cycles of induction therapy, a stem cell transplant, and two years of maintenance therapy. He has been off all treatment since March of 2016. Andrew has been an avid cyclist for many years and credits his devotion to exercise with his ability to withstand his treatments with little in the way of serious side effects. Since retiring from full-time employment in 2015 Andrew has increased his time on the bike cycling for over 10,000 miles in three consecutive years. This is Andrew’s first participation in a fundraising event sponsored by the MMRF.

My Goals: Stay Alive. Help Other Patients. Raise Funds & Awareness for MM.
Andrew Gordon
e. New treatments are being approved regularly but more money is needed to continue the fight. Secondly, by reaching out to potential donors I have helped to increase awareness about…
Read More
09/14/2019
The mission of the Multiple Myeloma Research Foundation (MMRF) is to find a cure for multiple myeloma by relentlessly pursuing innovation that accelerates the development of next-generation treatments to extend the lives of patients. Founded in 1998 by Kathy Giusti, a multiple myeloma patient, and her twin sister Karen Andrews as a 501(c) (3) nonprofit organization, the MMRF is a world-recognized leader in cancer research. Together with its partners, the MMRF has created the only end-to-end solution in precision medicine and the single largest genomic dataset in all cancers. The MMRF continues to disrupt the industry today, as a pioneer and leader at the helm of new research efforts. Since its inception, the organization has raised over $400 million and directs nearly 90% of the total funds to research and related programs. Learn more and sign up to receive news and resources from the MMRF.

Learn More

At Janssen Oncology, we’re shaping the future of cancer treatment. In the process, we’re striving to change expectations of what a cancer diagnosis means. Our purpose is driven by an urgency and commitment to bringing transformational cancer solutions to the people who need them. Passionate about our work, we are driven by the personal connection many of us share with the disease. With our partners, we focus on delivering solutions that make a positive impact on human health. We are part of Janssen Biotech, Inc., and the Janssen Pharmaceutical Companies of Johnson & Johnson.

About Janssen Oncology

Click below to learn more about a treatment option for multiple myeloma. If you’re also interested in getting more information from Janssen, sign up for ongoing communications.

Learn More